Home › NDC Lookup › RxCUI directory › RxCUI 198200

Rifabutin 150 MG Oral Capsule — RxCUI 198200

RxNorm drug concept · Semantic clinical drug
RxCUI 198200 Semantic clinical drug · SCD ● Current RxNorm concept 7 FDA products 8 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI198200
Official nameRifabutin 150 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped7
Package NDCs mapped8
Reported Medicaid activity (SDUD)7,739 prescriptions · 29 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Rifabutin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Rifabutin is prescribed to help prevent a serious infection called disseminated MAC — short for Mycobacterium avium complex. This is a bacterial infection that can spread throughou...
  • What exactly is rifabutin protecting me from?
  • Yes, completely normal and nothing to worry about. About 30% of people taking rifabutin notice a reddish-orange or brown discoloration of their urine — it's one of the most common...
  • My urine looks orange-brown — is that normal?
📖 Read our full Rifabutin guide →

🕸️ Concept Web — How Rifabutin 150 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Rifabutin 150 MG Oral Capsule RxCUI 198200

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Rifabutin 55672
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Mycobutin 227450
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Rifabutin Oral Capsule 373780
    • Rifabutin Oral Product 1165458
    • Rifabutin Pill 1165459
    • Rifabutin Oral Capsule [Mycobutin] 366733
    • Mycobutin Oral Product 1184425
    • Mycobutin Pill 1184426
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Rifabutin 150 MG 316640
    • Rifabutin 150 MG Oral Capsule [Mycobutin] 103899
    • Rifabutin 150 MG [Mycobutin] 563439

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Rifabutin 150 MG SCDC · 316640
  • Rifabutin Oral Capsule SCDF · 373780
  • Rifabutin Oral Product SCDG · 1165458
  • Rifabutin Pill SCDG · 1165459

Brand-Name Concepts

  • Rifabutin 150 MG Oral Capsule [Mycobutin] SBD · 103899
  • Rifabutin 150 MG [Mycobutin] SBDC · 563439
  • Rifabutin Oral Capsule [Mycobutin] SBDF · 366733
  • Mycobutin Oral Product SBDG · 1184425
  • Mycobutin Pill SBDG · 1184426
  • Mycobutin BN · 227450

📦 FDA Products & Package NDCs

7 products · 8 package NDCs
8 package NDCs map to RxCUI 198200 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
10135-0738-01 100 CAPSULE in 1 BOTTLE (10135-738-01) Rifabutin Marlex Pharmaceuticals, Inc. 2022-05-01
59762-1350-01 100 CAPSULE in 1 BOTTLE (59762-1350-1) Rifabutin Mylan Pharmaceuticals Inc. 2014-04-07
70518-4254-00 60 CAPSULE in 1 BOTTLE, PLASTIC (70518-4254-0) Rifabutin REMEDYREPACK INC. 2025-01-13
70518-4594-00 60 CAPSULE in 1 BOTTLE, PLASTIC (70518-4594-0) Rifabutin REMEDYREPACK INC. 2026-03-24
70518-4594-01 50 POUCH in 1 BOX (70518-4594-1) / 1 CAPSULE in 1 POUCH (70... Rifabutin REMEDYREPACK INC. 2026-06-05
70954-0041-10 100 CAPSULE in 1 BOTTLE (70954-041-10) Rifabutin ANI Pharmaceuticals, Inc. 2021-12-17
72319-0010-04 100 CAPSULE in 1 BOTTLE (72319-010-04) Rifabutin i3 Pharmaceuticals, LLC 2026-04-16
73141-0020-04 100 CAPSULE in 1 BOTTLE (73141-020-04) Rifabutin A2A Integrated Pharmaceuticals 2026-05-15
Observed labelers: REMEDYREPACK INC. (3) · A2A Integrated Pharmaceuticals (1) · ANI Pharmaceuticals, Inc. (1) · i3 Pharmaceuticals, LLC (1) · Marlex Pharmaceuticals, Inc. (1) · Mylan Pharmaceuticals Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$9.0755
Range $9.0755–$9.0755 · middle 50% $9.0755–$9.0755 · 3 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.